Skip to main content
Top
Published in: BMC Public Health 1/2018

Open Access 01-12-2018 | Study protocol

Estimating the incidence of enteric fever in children in India: a multi-site, active fever surveillance of pediatric cohorts

Authors: Jacob John, Ashish Bavdekar, Temsunaro Rongsen-Chandola, Shanta Dutta, Gagandeep Kang, NSSEFI Collaborators

Published in: BMC Public Health | Issue 1/2018

Login to get access

Abstract

Background

Salmonella Typhi is responsible for about 20 million episodes of illness and over 140,000 deaths annually globally. South Asia has the highest documented burden of typhoid and is home to the multi-drug resistant H58 strain that makes treatment more challenging. The WHO recommends the use of Typhoid Conjugate Vaccines in typhoid endemic countries. Decisions on the preferred immunization strategy should be based on an analysis of disease burden, availability, affordability, and operational feasibility. Typhoid vaccines have so far remained unimplemented as public health measures because of a perceived decline in typhoid burden in recent years. The apparent decline, based on hospital reports, may be a result of rampant antimicrobial use in the community and therefore estimation of disease incidence at the community is necessary to better measure disease incidence and transmission.

Methods

Age-specific incidence of typhoid fever in children between 6 months and 15 years will be estimated in four community based cohorts in varied settings across India using standardized protocols for active fever surveillance in the community. Data will be collected on secured cloud infrastructure using a combination of android and web-based real-time data collection tools. Blood cultures will be done for children with fever lasting 3 or more consecutive days using automated blood culture systems. Those with blood-culture confirmed typhoid fever will be followed up till 90 days to estimate costs and clinical outcomes of the illness episodes. Environmental factors, access to safe water, sanitation, hygiene, food hygiene, demography, population density and socioeconomic status will be assessed periodically to characterise risk factors and permit extrapolation of burden to similar risk settings.

Discussion

With the availability of licensed typhoid conjugated vaccines in India, it is important to consider whether the burden of disease is present and sufficient to require the use of vaccine in addition to other interventions. Active case finding in the community permits the detection of cases that would be missed in facility-based surveillance systems. Understanding the age distribution, burden, cost-of-illness and transmission of disease is essential to plan interventions and predict their potential impact.

Trial registration

The surveillance has been prospectively registered in the Clinical Trial Registry of India (CTRI/​2017/​09/​009719) on 12 September 2017.
Literature
1.
2.
go back to reference Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health. 2012;2(1):010401.CrossRefPubMedPubMedCentral Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health. 2012;2(1):010401.CrossRefPubMedPubMedCentral
3.
go back to reference Bahl R, Sinha A, Poulos C, Whittington D, Sazawal S, Kumar R, et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr. 2004;22(3):304–10.PubMed Bahl R, Sinha A, Poulos C, Whittington D, Sazawal S, Kumar R, et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr. 2004;22(3):304–10.PubMed
4.
go back to reference Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of vi typhoid vaccine in India. N Engl J Med. 2009;361(4):335–44.CrossRefPubMed Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of vi typhoid vaccine in India. N Engl J Med. 2009;361(4):335–44.CrossRefPubMed
5.
go back to reference Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86(4):260–8.CrossRefPubMedPubMedCentral Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86(4):260–8.CrossRefPubMedPubMedCentral
6.
go back to reference Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec. 2008;83(6):49-59. PubMed PMID: 18260212. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec. 2008;83(6):49-59. PubMed PMID: 18260212.
7.
go back to reference Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000;44(7):1855–9.CrossRefPubMedPubMedCentral Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000;44(7):1855–9.CrossRefPubMedPubMedCentral
8.
go back to reference Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002;347(22):1770–82.CrossRefPubMed Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002;347(22):1770–82.CrossRefPubMed
9.
go back to reference Parry CM, Ho VA, Phuong l T, Bay PV, Lanh MN, Tung l T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother. 2007;51(3):819–25.CrossRefPubMed Parry CM, Ho VA, Phuong l T, Bay PV, Lanh MN, Tung l T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother. 2007;51(3):819–25.CrossRefPubMed
10.
go back to reference Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al. Typhoid fever in children aged less than 5 years. Lancet. 1999;354(9180):734–7.CrossRefPubMed Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al. Typhoid fever in children aged less than 5 years. Lancet. 1999;354(9180):734–7.CrossRefPubMed
11.
go back to reference Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, et al. Safety and immunogenicity of a vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61(3):393–402.CrossRefPubMed Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, et al. Safety and immunogenicity of a vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61(3):393–402.CrossRefPubMed
12.
go back to reference Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390(10111):2472–80.CrossRefPubMedPubMedCentral Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390(10111):2472–80.CrossRefPubMedPubMedCentral
13.
go back to reference John J, Van Aart CJ, Grassly NC. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis. PLoS Negl Trop Dis. 2016;10(4):e0004616.CrossRefPubMedPubMedCentral John J, Van Aart CJ, Grassly NC. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis. PLoS Negl Trop Dis. 2016;10(4):e0004616.CrossRefPubMedPubMedCentral
14.
go back to reference Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2(10):e570–80.CrossRefPubMed Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2(10):e570–80.CrossRefPubMed
15.
go back to reference Baker S, Duy PT, Nga TV, Dung TT, Phat VV, Chau TT, et al. Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure. elife. 2013;2:e01229.CrossRefPubMedPubMedCentral Baker S, Duy PT, Nga TV, Dung TT, Phat VV, Chau TT, et al. Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure. elife. 2013;2:e01229.CrossRefPubMedPubMedCentral
16.
go back to reference Divyashree S, Nabarro LE, Veeraraghavan B, Rupali P. Enteric fever in India: current scenario and future directions. Tropical Med Int Health. 2016;21(10):1255–62.CrossRef Divyashree S, Nabarro LE, Veeraraghavan B, Rupali P. Enteric fever in India: current scenario and future directions. Tropical Med Int Health. 2016;21(10):1255–62.CrossRef
Metadata
Title
Estimating the incidence of enteric fever in children in India: a multi-site, active fever surveillance of pediatric cohorts
Authors
Jacob John
Ashish Bavdekar
Temsunaro Rongsen-Chandola
Shanta Dutta
Gagandeep Kang
NSSEFI Collaborators
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2018
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-018-5498-2

Other articles of this Issue 1/2018

BMC Public Health 1/2018 Go to the issue